Bioscience Health Innovations Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission, reporting a net loss for both the three-month and nine-month periods ending on that date.

Key Highlights

  • Q3 2026 Revenue: The company reported revenues of $970,071 for the three months ended September 30, 2026, compared to $1,131,427 in the same period of 2025, according to the filing.
  • Q3 2026 Net Loss: The company recorded a net loss of $149,225 for the three months ended September 30, 2026, versus a net loss of $8,782 in the prior-year quarter.
  • Nine-Month Net Loss: For the nine months ended September 30, 2026, the company reported a net loss of $564,885, compared to net income of $875,720 for the same period in 2025.
  • Total Assets Increased: Total assets grew to $3,204,228 as of September 30, 2026, up from $1,707,181 as of December 31, 2025.
  • Cash Position: Cash and cash equivalents stood at $1,691,858 at September 30, 2026, compared to $661,925 at December 31, 2025.
  • Common Shares Outstanding: As of November 12, 2026, there were 12,027,217 shares of common stock outstanding, up from 10,979,058 at December 31, 2025.
  • New Share Issuances: During the nine months ended September 30, 2026, the company issued a total of 1,048,159 common shares for cash proceeds recorded across three quarters.

Bioscience Health Innovations Financial Results for the Quarter Ended September 30, 2026

According to the filing, Bioscience Health Innovations Inc. - whose common stock is registered pursuant to Section 12(g) of the Exchange Act with no exchange listing disclosed on the cover page - reported revenues of $970,071 for the three months ended September 30, 2026, down from $1,131,427 in the comparable 2025 quarter. Cost of goods sold for the same three-month period was $332,507, yielding a gross profit of $637,564. Total operating expenses for Q3 2026 were $785,824, comprised of $720,121 in general and administrative expenses and $65,703 in consulting fees, resulting in a loss from operations of $148,260.

For the nine months ended September 30, 2026, the company reported revenues of $2,757,381, down from $4,115,960 in the first nine months of 2025, the filing disclosed. Nine-month gross profit was $1,782,643, while total operating expenses reached $2,378,692, producing a loss from operations of $596,049. After interest expense of $965 and an income tax expense of $32,129, the net loss for the nine-month period was $564,885, compared to net income of $875,720 for the same period in 2025. Loss per common share - basic and diluted - was $(0.05) for the nine months ended September 30, 2026.

The balance sheet as of September 30, 2026 showed total stockholders' equity of $2,922,712, reflecting accumulated deficit of $263,878 and additional paid-in capital of $3,185,373. The company issued 437,067 common shares for cash in Q1 2026, 336,204 shares in Q2 2026, and 274,888 shares in Q3 2026, according to the statements of stockholders' equity. The company identified itself as a smaller reporting company and an emerging growth company, and indicated it is not a shell company.

What Was Disclosed

Bioscience Health Innovations Inc. filed its quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $149,225, a nine-month net loss of $564,885, total assets of $3,204,228, and 12,027,217 shares outstanding as of November 12, 2026.